163 related articles for article (PubMed ID: 17562253)
1. Clinical benefits and economic analysis of pegylated liposomal doxorubicin/vincristine/dexamethasone versus doxorubicin/vincristine/dexamethasone in patients with newly diagnosed multiple myeloma.
Porter CA; Rifkin RM
Clin Lymphoma Myeloma; 2007 Apr; 7 Suppl 4():S150-5. PubMed ID: 17562253
[TBL] [Abstract][Full Text] [Related]
2. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial.
Rifkin RM; Gregory SA; Mohrbacher A; Hussein MA
Cancer; 2006 Feb; 106(4):848-58. PubMed ID: 16404741
[TBL] [Abstract][Full Text] [Related]
3. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
Hussein MA; Wood L; Hsi E; Srkalovic G; Karam M; Elson P; Bukowski RM
Cancer; 2002 Nov; 95(10):2160-8. PubMed ID: 12412170
[TBL] [Abstract][Full Text] [Related]
4. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.
Zervas K; Dimopoulos MA; Hatzicharissi E; Anagnostopoulos A; Papaioannou M; Mitsouli Ch; Panagiotidis P; Korantzis J; Tzilianos M; Maniatis A;
Ann Oncol; 2004 Jan; 15(1):134-8. PubMed ID: 14679133
[TBL] [Abstract][Full Text] [Related]
5. Role of liposomal anthracyclines in the treatment of multiple myeloma.
Hussein MA; Anderson KC
Semin Oncol; 2004 Dec; 31(6 Suppl 13):147-60. PubMed ID: 15717741
[TBL] [Abstract][Full Text] [Related]
6. Administration of a modified chemotherapeutic regimen containing vincristine, liposomal doxorubicin and dexamethasone to multiple myeloma patients: preliminary data.
Tsiara SN; Kapsali E; Christou L; Panteli A; Pritsivelis N; Bourantas KL
Eur J Haematol; 2000 Aug; 65(2):118-22. PubMed ID: 10966172
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma.
Hussein MA; Baz R; Srkalovic G; Agrawal N; Suppiah R; Hsi E; Andresen S; Karam MA; Reed J; Faiman B; Kelly M; Walker E
Mayo Clin Proc; 2006 Jul; 81(7):889-95. PubMed ID: 16835968
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
[TBL] [Abstract][Full Text] [Related]
9. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma.
Dimopoulos MA; Pouli A; Zervas K; Grigoraki V; Symeonidis A; Repoussis P; Mitsouli C; Papanastasiou C; Margaritis D; Tokmaktsis A; Katodritou I; Kokkini G; Terpos E; Vyniou N; Tzilianos M; Chatzivassili A; Kyrtsonis MC; Panayiotidis P; Maniatis A;
Ann Oncol; 2003 Jul; 14(7):1039-44. PubMed ID: 12853344
[TBL] [Abstract][Full Text] [Related]
10. Pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone as first-line therapy for multiple myeloma.
Hussein M
Clin Lymphoma; 2003 Aug; 4 Suppl 1():S18-22. PubMed ID: 14556672
[TBL] [Abstract][Full Text] [Related]
11. A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma.
Cook G; Clark RE; Morris TC; Robertson M; Lucie NP; Anderson S; Paul J; Franklin IM
Br J Haematol; 2004 Sep; 126(6):792-8. PubMed ID: 15352982
[TBL] [Abstract][Full Text] [Related]
12. A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study.
Hunault-Berger M; Leguay T; Thomas X; Legrand O; Huguet F; Bonmati C; Escoffre-Barbe M; Legros L; Turlure P; Chevallier P; Larosa F; Garban F; Reman O; Rousselot P; Dhédin N; Delannoy A; Lafage-Pochitaloff M; Béné MC; Ifrah N; Dombret H;
Haematologica; 2011 Feb; 96(2):245-52. PubMed ID: 20971822
[TBL] [Abstract][Full Text] [Related]
13. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group.
Zervas K; Mihou D; Katodritou E; Pouli A; Mitsouli CH; Anagnostopoulos A; Delibasi S; Kyrtsonis MC; Anagnostopoulos N; Terpos E; Zikos P; Maniatis A; Dimopoulos MA;
Ann Oncol; 2007 Aug; 18(8):1369-75. PubMed ID: 17693650
[TBL] [Abstract][Full Text] [Related]
14. Pegylated liposomal doxorubicin and immunomodulatory drug combinations in multiple myeloma: rationale and clinical experience.
Chanan-Khan AA; Lee K
Clin Lymphoma Myeloma; 2007 Apr; 7 Suppl 4():S163-9. PubMed ID: 17562255
[TBL] [Abstract][Full Text] [Related]
15. An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.
Nishihori T; Baz R; Shain K; Kim J; Ochoa-Bayona JL; Yue B; Sullivan D; Dalton W; Alsina M
Eur J Haematol; 2015 Nov; 95(5):426-35. PubMed ID: 25600676
[TBL] [Abstract][Full Text] [Related]
16. Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma.
Jo JC; Kang BW; Sym SJ; Lee SS; Jang G; Kim S; Lee DH; Kim SW; Lee JS; Suh C
Invest New Drugs; 2011 Feb; 29(1):175-81. PubMed ID: 19823768
[TBL] [Abstract][Full Text] [Related]
17. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
18. A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients.
Berenson JR; Yellin O; Chen CS; Patel R; Bessudo A; Boccia RV; Yang HH; Vescio R; Yung E; Mapes R; Eades B; Hilger JD; Wirtschafter E; Hilger J; Nassir Y; Swift RA
Br J Haematol; 2011 Dec; 155(5):580-7. PubMed ID: 21950583
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
[TBL] [Abstract][Full Text] [Related]
20. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
